Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3 with dissociation constants (K D) of 47.0 nM and 9.4 nM for PSMA and CD3, respectively. It is utilized in the study of metastatic castration-resistant prostate cancer (mCRPC) [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3 with dissociation constants (K D) of 47.0 nM and 9.4 nM for PSMA and CD3, respectively. It is utilized in the study of metastatic castration-resistant prostate cancer (mCRPC) [1] [2]. |
Molecular Weight | N/A |
CAS No. | 1442657-12-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pasotuxizumab 1442657-12-6 inhibitor inhibit